Cite
HARVARD Citation
Van Vollenhoven, R. et al. (n.d.). S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. Lupus science & medicine. p. A16. [Online].